Tonix Pharmaceuticals is a development stage specialty pharmaceutical company, which focuses on the development of pharmaceutical products for the disorders of central nervous system. The Company's lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Tonix is also developing TNX-601, a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder; and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.